SECTION 1. IDENTIFICATION

Product name: Ertugliflozin (< 5%) / Sitagliptin Formulation
Other means of identification: No data available

Manufacturer or supplier's details
Company name of supplier: Merck & Co., Inc
Address: 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone: 908-740-4000
Telefax: 908-735-1496
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations
Skin irritation: Category 2
Serious eye damage: Category 1
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Kidney, Stomach, Prostate)

GHS label elements
Hazard pictograms:
Signal Word: Danger
Hazard Statements: H315 Causes skin irritation.
H318 Causes serious eye damage.
H373 May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

Precautionary Statements: Prevention:
P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ eye protection/ face protection.
Response:
P302 + P352 IF ON SKIN: Wash with plenty of water.
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor.
P314 Get medical advice/ attention if you feel unwell.
SAFETY DATA SHEET

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version: 2.2  Revision Date: 09/13/2019  SDS Number: 2400336-00005  Date of last issue: 04/24/2019

P332 + P313 If skin irritation occurs: Get medical advice/attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>654671-77-9</td>
<td>&gt;= 30 - &lt; 60</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&gt;= 10 - &lt; 30</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td>&gt;= 1 - &lt; 5</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>&gt;= 1 - &lt; 5</td>
</tr>
</tbody>
</table>

Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes skin irritation.
Causes serious eye damage.
May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

2 / 20
SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides
Oxides of phosphorus

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE
4 / 20

SAFETY DATA SHEET

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 2.2  Revision Date: 09/13/2019  SDS Number: 2400336-00005  Date of last issue: 04/24/2019  Date of first issue: 02/01/2018

Technical measures:
Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
Keep in properly labeled containers.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>654671-77-9</td>
<td>TWA</td>
<td>0.5 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Total dust)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable dust fraction)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWAEV (total dust)</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Ertugliflozin</td>
<td>1210344-83-4</td>
<td>TWA</td>
<td>10 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable fraction)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable fraction)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>
Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection: Chemical-resistant gloves

Remarks: Consider double gloving.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a face shield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder

Color: No data available

Odor: No data available

Odor Threshold: No data available

pH: No data available
Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)
  Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
  Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions
  : May form explosive dust-air mixture during processing, handling or other means.
  Can react with strong oxidizing agents.
Conditions to avoid: Heat, flames and sparks.
Avoid dust formation.

Incompatible materials: Oxidizing agents

Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:
Sitagliptin:
Acute oral toxicity: LD50 (Rat): > 3,000 mg/kg
LD50 (Mouse): 3,000 mg/kg

Cellulose:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

Ertugliflozin:
Acute oral toxicity: LD50 (Rat): 500 mg/kg
Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available

Magnesium stearate:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials
Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
   Remarks: Based on data from similar materials

Skin corrosion/irritation:
Causes skin irritation.

Components:

Sitagliptin:
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Ertugliflozin:
Result: Corrosive

Magnesium stearate:
Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials

Serious eye damage/eye irritation:
Causes serious eye damage.

Components:

Sitagliptin:
Species: Rabbit
Result: Irritating to eyes.
Method: Draize Test

Ertugliflozin:
Result: Severe irritation

Magnesium stearate:
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

Respiratory or skin sensitization:

Skin sensitization:
Not classified based on available information.

Respiratory sensitization:
Not classified based on available information.

Components:

Sitagliptin:
Test Type: Local lymph node assay (LLNA)
Ertugliflozin (< 5%) / Sitagliptin Formulation

<table>
<thead>
<tr>
<th>Component</th>
<th>Test Type</th>
<th>Result</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ertugliflozin</td>
<td>Local lymph node assay (LLNA)</td>
<td>Not a skin sensitizer.</td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>Maximization Test</td>
<td>negative</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Germ cell mutagenicity
Not classified based on available information.

Components:

**Sitagliptin:**

Genotoxicity in vitro:
- Test Type: Ames test
  - Result: negative

Genotoxicity in vivo:
- Test Type: Micronucleus test
  - Species: Mouse
  - Application Route: Oral
  - Result: negative

**Cellulose:**

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Ingestion
  - Result: negative
Ertugliflozin (< 5%) / Sitagliptin Formulation

**SAFETY DATA SHEET**

**Ertugliflozin:**
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: Chromosome aberration test in vitro
  - Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Rat
  - Result: negative

**Magnesium stearate:**
Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative
  - Remarks: Based on data from similar materials
- Test Type: Chromosome aberration test in vitro
  - Method: OECD Test Guideline 473
  - Result: negative
  - Remarks: Based on data from similar materials
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
  - Remarks: Based on data from similar materials

**Carcinogenicity**
Not classified based on available information.

**Components:**

**Sitagliptin:**
- Species: Mouse
- Application Route: Oral
- Exposure time: 2 Years
- Result: negative

- Species: Rat
- Application Route: oral (drinking water)
- Exposure time: 2 Years
- Result: positive
- Target Organs: Liver
- Remarks: Significant toxicity observed in testing

**Carcinogenicity - Assessment**: Weight of evidence does not support classification as a carcinogen

**Cellulose:**
- Species: Rat
- Application Route: Ingestion
- Exposure time: 72 weeks
- Result: negative
SAFETY DATA SHEET

Ertugliflozin (< 5%) / Sitagliptin Formulation

Version: 2.2  Revision Date: 09/13/2019  SDS Number: 2400336-00005  Date of last issue: 04/24/2019

Ertugliflozin:
Species: Mouse  Application Route: Oral  Exposure time: 2 Years  Result: negative
Species: Rat  Application Route: Oral  Exposure time: 2 Years  Result: negative

Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

Reproductive toxicity
Not classified based on available information.

Components:

Sitagliptin:
Effects on fertility: Test Type: Fertility/early embryonic development  Species: Rat  Application Route: Oral  Fertility: NOAEL Parent: 1,000 mg/kg body weight  Result: Animal testing did not show any effects on fertility.

Effects on fetal development: Test Type: Embryo-fetal development  Species: Rat  Application Route: Oral  Teratogenicity: LOAEL: 250 mg/kg body weight  Result: Embryotoxic effects and adverse effects on the offspring were detected. No teratogenic effects.

Test Type: Embryo-fetal development  Species: Rabbit  Teratogenicity: NOAEL: 125 mg/kg body weight  Result: No teratogenic effects.

Cellulose:
Effects on fertility: Test Type: One-generation reproduction toxicity study  Species: Rat  Application Route: Ingestion  Result: negative

Effects on fetal development: Test Type: Fertility/early embryonic development  Species: Rat  Application Route: Ingestion  Result: negative

Ertugliflozin:
Effects on fertility: Test Type: Fertility/early embryonic development  Species: Rat  Application Route: Oral
SAFETY DATA SHEET
Ertugliflozin (< 5%) / Sitagliptin Formulation

Fertility: NOAE: 250 mg/kg body weight
Remarks: Maternal toxicity observed.
No significant adverse effects were reported

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Oral
Fertility: NOAEL: 200 mg/kg body weight
Remarks: No significant adverse effects were reported

Effects on fetal development:
Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 50 mg/kg body weight
Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 250 mg/kg body weight
Remarks: No significant adverse effects were reported

Magnesium stearate:
Effects on fertility:
Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development:
Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

Components:

Ertugliflozin:
Routes of exposure: Oral
Target Organs: Kidney, Stomach, Prostate
Assessment: May cause damage to organs through prolonged or repeated exposure.
Repeated dose toxicity

**Components:**

**Sitagliptin:**
- **Species:** Mouse
- **NOAEL:** 500 mg/kg
- **LOAEL:** 1,000 mg/kg
- **Application Route:** Oral
- **Exposure time:** > 2 y
- **Target Organs:** Kidney

- **Species:** Rat
- **NOAEL:** 500 mg/kg
- **LOAEL:** 1,000 mg/kg
- **Application Route:** Oral
- **Exposure time:** 14 Weeks
- **Target Organs:** Liver, Kidney, Heart, Teeth

- **Species:** Dog
- **NOAEL:** 10 mg/kg
- **LOAEL:** 50 mg/kg
- **Application Route:** Oral
- **Exposure time:** 53 Weeks
- **Target Organs:** Central nervous system
- **Symptoms:** Loss of balance
- **Remarks:** The mechanism or mode of action may not be relevant in humans.

- **Species:** Dog
- **NOAEL:** 2 mg/kg
- **LOAEL:** 10 mg/kg
- **Application Route:** Oral
- **Exposure time:** 27 Weeks
- **Target Organs:** Skeletal muscle, Central nervous system
- **Symptoms:** Loss of balance
- **Remarks:** The mechanism or mode of action may not be relevant in humans.

- **Species:** Monkey
- **NOAEL:** 100 mg/kg
- **Application Route:** Oral
- **Exposure time:** 14 Weeks
- **Remarks:** No significant adverse effects were reported

**Cellulose:**
- **Species:** Rat
- **NOAEL:** >= 9,000 mg/kg
- **Application Route:** Ingestion
- **Exposure time:** 90 Days

**Ertugliflozin:**
- **Species:** Rat
- **LOAEL:** 500 mg/kg
**SAFETY DATA SHEET**

**Ertugliflozin (< 5%) / Sitagliptin Formulation**

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
<tr>
<td>Species</td>
<td>Rat</td>
</tr>
<tr>
<td>LOAEL</td>
<td>250 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

**Species**
- Rat
  - LOAEL: 250 mg/kg
  - Application Route: Oral
  - Exposure time: 30 d
  - Target Organs: Kidney

**Species**
- Rat
  - LOAEL: 25 mg/kg
  - Application Route: Oral
  - Exposure time: 180 d
  - Target Organs: Kidney, Bone, Stomach

**Species**
- Dog
  - NOAEL: 150 mg/kg
  - Application Route: Oral
  - Exposure time: 270 d
  - Remarks: No significant adverse effects were reported

**Species**
- Mouse
  - NOAEL: 100 mg/kg
  - Application Route: Oral
  - Exposure time: 90 d
  - Remarks: No significant adverse effects were reported

**Species**
- Mouse
  - NOAEL: > 100 mg/kg
  - Application Route: Ingestion
  - Exposure time: 90 Days
  - Remarks: Based on data from similar materials

**Magnesium stearate:**
- Rat
  - NOAEL: > 100 mg/kg
  - Application Route: Ingestion
  - Exposure time: 90 Days
  - Remarks: Based on data from similar materials

**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

**Components:**

**Sitagliptin:**
Inhalation: Symptoms: upper respiratory tract infection, pharyngitis, Headache

Ingestion: Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhea

**Ertugliflozin:**
Ingestion: Symptoms: The most common side effects are: Headache, constipation, Diarrhea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection

### SECTION 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

**Components:**

**Sitagliptin:**
- **Toxicity to fish:** LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 203
- **Toxicity to daphnia and other aquatic invertebrates:** EC50 (Daphnia magna (Water flea)): 60 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202
- **Toxicity to algae/aquatic plants:** EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 201
  NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 201
- **Toxicity to fish (Chronic toxicity):** NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l
  Exposure time: 33 d
  Method: OECD Test Guideline 210
- **Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):** NOEC (Daphnia magna (Water flea)): 9.8 mg/l
  Exposure time: 21 d
  Method: OECD Test Guideline 211
- **Toxicity to microorganisms:** EC50: > 150 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition
  Method: OECD Test Guideline 209
  NOEC: 150 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition

**Cellulose:**
- **Toxicity to fish:** LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

**Ertugliflozin:**

- **Toxicity to algae/aquatic plants:** EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- **NOEC (Pseudokirchneriella subcapitata (green algae)):** 50 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201

- **Toxicity to fish (Chronic toxicity):** NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
  - Exposure time: 32 d
  - Method: OECD Test Guideline 210
  - Remarks: No toxicity at the limit of solubility.

- **Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):** NOEC (Daphnia magna (Water flea)): 2.14 mg/l
  - Exposure time: 21 d
  - Method: OECD Test Guideline 211
  - Remarks: No toxicity at the limit of solubility.

- **Toxicity to microorganisms:** EC50: > 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

  - NOEC: 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209

**Magnesium stearate:**

- **Toxicity to fish:** LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
  - Exposure time: 48 h
  - Method: DIN 38412
  - Remarks: Based on data from similar materials

- **Toxicity to daphnia and other aquatic invertebrates:** EL50 (Daphnia magna (Water flea)): > 1 mg/l
  - Exposure time: 47 h
  - Test substance: Water Accommodated Fraction
  - Remarks: Based on data from similar materials
  - No toxicity at the limit of solubility.

- **Toxicity to algae/aquatic plants:** EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
  - Exposure time: 72 h
  - Test substance: Water Accommodated Fraction
  - Method: OECD Test Guideline 201
  - Remarks: Based on data from similar materials
  - No toxicity at the limit of solubility.
NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms:
EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Sitagliptin:
Biodegradability:
- Result: not rapidly degradable
- Biodegradation: 39.7 %
- Exposure time: 28 d
- Method: OECD Test Guideline 314

Stability in water:
- Hydrolysis: 50 % (401 d)
- Method: OECD Test Guideline 111

Cellulose:
Biodegradability:
- Result: Readily biodegradable.

Ertugliflozin:
Biodegradability:
- Result: Not readily biodegradable.
- Biodegradation: 40.8 %
- Exposure time: 28 d

Magnesium stearate:
Biodegradability:
- Result: Not biodegradable.
- Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Sitagliptin:
Partition coefficient: n-octanol/water:
- log Pow: -0.03

Ertugliflozin:
Partition coefficient: n-octanol/water:
- log Pow: 2.47

Magnesium stearate:
Partition coefficient: n-octanol/water:
- log Pow: > 4
Mobility in soil

Components:

Sitagliptin:
Distribution among environmental compartments: \( \log \text{Koc}: 4.37 \)

Ertugliflozin:
Distribution among environmental compartments: \( \log \text{Koc}: 2.88 \)

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

TDG
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS: not determined

DSL: not determined

IECSC: not determined
SECTION 16. OTHER INFORMATION

**Full text of other abbreviations**

ACGIH: USA. ACGIH Threshold Limit Values (TLV)
CA BC OEL: Canada. British Columbia OEL
CA QC OEL: Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA: 8-hour, time-weighted average
CA AB OEL / TWA: 8-hour Occupational exposure limit
CA BC OEL / TWA: 8-hour time weighted average
CA QC OEL / TWA: Time-weighted average exposure value


Revision Date: 09/13/2019
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.